Development of a Cancer Vaccine Targeting Tumor Blood Vessels
Explore this paper's citation graph
Summary
It is concluded that it is possible to replace the mineral oil based adjUvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic.
- Type
- article
- Published
- 2012-01-01
- Cited by
- 2
- References
- 431
- Access
- Open access
- OpenAlex
- https://openalex.org/W19710989
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:44179611
Keywords
Adjuvant, Medicine, CpG Oligodeoxynucleotide, Immune system, Immunization
References
- Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease
- Toll-like receptor 2–mediated NF-κB activation requires a Rac1-dependent pathway
- Myofibroblasts and mechano-regulation of connective tissue remodelling
- Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin
- Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts.
- The mode of action of mineral-oil emulsion adjuvants on antibody production in mice.
- Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
- Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
- Expression of tenascin-C and its isoforms in the breast
- The role of VEGF in the regulation of physiological and pathological angiogenesis.
- The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.
- A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results
- PDGF and vessel maturation.
- Complement. Second of two parts.
- Tenascin and other adhesion-modulating proteins in cancer.
- Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells.
- The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis.
- Production and purification of monoclonal antibodies.
- Participation of C3 and its ligands in complement activation.
- Tenascin: cDNA cloning and induction by TGF‐beta.
Cited by
Related papers
- The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
- Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants.
- Tumor eradication by immunotherapy with biodegradable PLGA microspheres—an alternative to incomplete Freund's adjuvant
- A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.
- Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
- Different Adjuvanticity of Incomplete Freund’s Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine
- CpG Oligodeoxynucleotide is an Effective Adjuvant for Transcutaneous Immunization
- Improved Immunogenicity and Efficacy of the Recombinant 19-Kilodalton Merozoite Surface Protein 1 by the Addition of Oligodeoxynucleotide and Aluminum Hydroxide Gel in a Murine Malaria Vaccine Model
- Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates.
- In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.